Forendo Therapeutics

Forendo Pharma is a drug discovery and development company with a core competence in tissue specific regulation of sex hormones. Forendo founders, Risto Lammintausta, Professors Matti Poutanen and Antti Perheentupa bring a unique mixture of scientific, development, and clinical expertise to develop first in class therapies for intracrine diseases. Forendo discovery and development efforts focus on 17-HSD1 inhibitors for the treatment of endometriosis and on earlier programs from its HSD platform for other hormone dependent diseases. The company is also developing Fispemifene, the first selective estrogen receptor modulator for the treatment of symptoms of low testosterone. Forendo is based in Turku, Finland.